Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | hypothetical protein, conserved | 0.0027 | 0.1898 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0.1898 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0.1898 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0.1898 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0027 | 0.1898 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0069 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0027 | 0.1898 | 0.1898 |
Schistosoma mansoni | tar DNA-binding protein | 0.0069 | 1 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0069 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0069 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0027 | 0.1898 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0069 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0069 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0069 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0069 | 1 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.005 | 0.626 | 0.5384 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.005 | 0.626 | 0.626 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0069 | 1 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0027 | 0.1898 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0.1898 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0069 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0069 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0069 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.